Physician profile
Christopher Snyder
NPI 1689678658
$1,402.67
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $601 · 2021: $317.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $213.95 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.18 | 2019-2021 | |
| Lilly USA, LLC | $176.04 | 2019-2021 | |
| Novo Nordisk INC | $129.29 | 2019-2021 | |
| Astellas Pharma US INC | $122.44 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $118.79 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $87.23 | 2019-2021 | |
| Amarin Pharma, INC. | $67.49 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $59.01 | 2019 | |
| Abbvie INC. | $53.03 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $40.71 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.10 | 2020-2021 | |
| Biogen, INC. | $25.88 | 2021 | |
| Amgen INC. | $23.51 | 2019 | |
| Eisai INC. | $21.16 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $15.00 | 2020 | |
| Circassia INC. | $13.19 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.67 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.